JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 2.73 HKD 5%
Market Cap: 1.1B HKD

JW (Cayman) Therapeutics Co Ltd
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

JW (Cayman) Therapeutics Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
EPS (Diluted)
-ÂĄ1
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
EPS (Diluted)
-ÂĄ3
CAGR 3-Years
21%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
EPS (Diluted)
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
EPS (Diluted)
ÂĄ0
CAGR 3-Years
23%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
EPS (Diluted)
ÂĄ0
CAGR 3-Years
-63%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
EPS (Diluted)
-ÂĄ1
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

JW (Cayman) Therapeutics Co Ltd
Glance View

Market Cap
1.1B HKD
Industry
Biotechnology

JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.

Intrinsic Value
8.53 HKD
Undervaluation 68%
Intrinsic Value
Price

See Also

What is JW (Cayman) Therapeutics Co Ltd's EPS (Diluted)?
EPS (Diluted)
-1.4 CNY

Based on the financial report for Dec 31, 2024, JW (Cayman) Therapeutics Co Ltd's EPS (Diluted) amounts to -1.4 CNY.

What is JW (Cayman) Therapeutics Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
3%

Over the last year, the EPS (Diluted) growth was 24%. The average annual EPS (Diluted) growth rates for JW (Cayman) Therapeutics Co Ltd have been 7% over the past three years , 3% over the past five years .

Back to Top